title: Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Di Benedetto
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Berretta
authors.forename: Nicola
authors.initials: N
authors.lastname: De Ruvo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tarantino
authors.forename: Giuseppe
authors.initials: G
authors.lastname: D'Amico
authors.forename: Roberto
authors.initials: R
authors.lastname: Ballarin
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: Iemmolo
authors.forename: Giorgio E
authors.initials: GE
authors.lastname: Gerunda
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D003131:Combined Modality Therapy; D016174:Hepacivirus; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology; D016031:Liver Transplantation; D008297:Male; D020360:Neoadjuvant Therapy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D020123:Sirolimus / Q000627:therapeutic use*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007166:Immunosuppressive Agents; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D020123:Sirolimus